Mary Wang
Women's Health · Philadelphia, PANPI 1427358076
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (56.9%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Coloplast accounts for 66.9% of it on its own, with 10 other manufacturers making up the rest. 2025 is the largest year on record at $4,049, more than ten times the $76 reported in 2021. Among women's health clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 72 payments — averaging $109.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Coloplast$5K
- Medtronic$1K
- 180 Medical, Inc.$523
- Sumitomo Pharma America, Inc.$200
- Dentsply IH AB$188
- Astellas Pharma US Inc$183
- plus $276 from 5 others
Across 1 payment — averaging $210.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Medtronic$210
What the payments were for
- Consulting fees$4,49257%
- Travel & lodging$2994%
- Food & beverage$3,02538%
- Education$831%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Coloplast | 20 | $5,284 |
| Medtronic | 12 | $1,244 |
| 180 Medical, Inc. | 11 | $523 |
| Sumitomo Pharma America, Inc. | 10 | $200 |
| Dentsply IH AB | 10 | $188 |
| Astellas Pharma US Inc | 2 | $183 |
| Urovant Sciences Inc | 1 | $120 |
| Boston Scientific | 1 | $56 |
| Urogen Pharma, Inc. | 2 | $46 |
| Dentsply IH Inc. | 2 | $38 |
| Ambu Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Luja Coude$2,866
- SPEEDICATH$2,102
- INTERSTIM$1,026
- GEMTESA$244
- Veozah$118
- NURO$105
How this compares
$7,899 in reported general payments places this provider in the 95th percentile of 250 women's health providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 548 | $401,606 |
| GemtesaVibegron | 399 | $329,170 |
| Methenamine Hippurate | 413 | $37,473 |
| Estradiol | 231 | $13,384 |
| Trospium Chloride ErTrospium Chloride | 64 | $10,037 |
| PremarinEstrogens, Conjugated | 15 | $6,395 |
| Solifenacin Succinate | 147 | $6,349 |
| Cefpodoxime Proxetil | 151 | $5,810 |
| Oxybutynin Chloride ErOxybutynin Chloride | 82 | $3,666 |
| Tamsulosin Hcl | 142 | $2,669 |
| YuvafemEstradiol | 11 | $2,494 |
| Tolterodine Tartrate ErTolterodine Tartrate | 25 | $2,297 |
| Fosfomycin Tromethamine | 17 | $2,090 |
| Trimethoprim | 37 | $1,516 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 95 | $1,081 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $183 | $401,606548 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $200 | $329,170399 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 250 women's health providers in Pennsylvania.
Other women's health in Philadelphia
- Shawana MoorePhiladelphia$72K
- Kassandra PetitPhiladelphia$10K
- Enjoli RogersPhiladelphia$3K
- Sara CollinsPhiladelphia$2K
- Megan CarulloPhiladelphia$1K
- Megan GilbertPhiladelphia$1K
- Renee WynnPhiladelphia$1K
- Allison StevensPhiladelphia$1K
- Andrea MartinPhiladelphia$931
- Sarah RowlandPhiladelphia$717
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.